For the treatment of esophageal cancer, how to inhibit its glycolytic pathway seems to provide a new idea for the development of new targeted anticancer drugs, and HIF-1 and V-ATPase may also be potential targets for inhibiting glycolysis (Son et al., 2016). The gene discussed is HIF1A; the disease is esophageal cancer.